Academic Journal
Clinical trial: the microbiological and immunological effects of synbiotic consumption – a randomized double-blind placebo-controlled study in active Crohn’s disease.
| العنوان: | Clinical trial: the microbiological and immunological effects of synbiotic consumption – a randomized double-blind placebo-controlled study in active Crohn’s disease. |
|---|---|
| المؤلفون: | Steed, H., Macfarlane, G. T., Blackett, K. L., Bahrami, B., Reynolds, N., Walsh, S. V., Cummings, J. H., Macfarlane, S. |
| المصدر: | Alimentary Pharmacology & Therapeutics; Oct2010, Vol. 32 Issue 7, p872-883, 12p, 1 Diagram, 1 Chart, 6 Graphs |
| مصطلحات موضوعية: | CROHN'S disease, IMMUNE response, MICROORGANISMS, PLACEBOS, BIFIDOBACTERIUM |
| مستخلص: | Aliment Pharmacol Ther 2010; 32: 872–883 Background Crohn’s disease is an inflammatory illness in which the immune response against gut microorganisms is believed to drive an abnormal immune response. Consequently, modification of mucosal bacterial communities, and the immune effects they elicit, might be used to modify the disease state. Aim To investigate the effects of synbiotic consumption on disease processes in patients with Crohn's disease. Methods A randomized, double-blind placebo-controlled trial was conducted involving 35 patients with active Crohn's disease, using a synbiotic comprising Bifidobacterium longum and Synergy 1. Clinical status was scored and rectal biopsies were collected at the start, and at 3- and 6-month intervals. Transcription levels of immune markers and mucosal bacterial 16S rRNA gene copy numbers were quantified using real-time PCR. Results Significant improvements in clinical outcomes occurred with synbiotic consumption, with reductions in both Crohn's disease activity indices ( P = 0.020) and histological scores ( P = 0.018). The synbiotic had little effect on mucosal IL-18, INF-γ and IL-1β; however, significant reductions occurred in TNF-α expression in synbiotic patients at 3 months ( P = 0.041), although not at 6 months. Mucosal bifidobacteria proliferated in synbiotic patients. Conclusion Synbiotic consumption was effective in improving clinical symptoms in patients with active Crohn's disease. [ABSTRACT FROM AUTHOR] |
| Copyright of Alimentary Pharmacology & Therapeutics is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| قاعدة البيانات: | Complementary Index |
Full Text Finder | ResultId |
1 |
|---|---|
| Header |
edb Complementary Index 53419056 834 6 Academic Journal academicJournal 833.779052734375 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edb&AN=53419056&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
Array ( [0] => Array ( [Url] => https://resolver.ebscohost.com/openurl?custid=s6537998&groupid=main&authtype=ip,guest&sid=EBSCO:edb&genre=article&issn=02692813&ISBN=&volume=32&issue=7&date=20101001&spage=872&pages=872-883&title=Alimentary Pharmacology & Therapeutics&atitle=Clinical%20trial%3A%20the%20microbiological%20and%20immunological%20effects%20of%20synbiotic%20consumption%20%E2%80%93%20a%20randomized%20double-blind%20placebo-controlled%20study%20in%20active%20Crohn%E2%80%99s%20disease.&id=DOI:10.1111/j.1365-2036.2010.04417.x [Name] => Full Text Finder (s6537998api) [Category] => fullText [Text] => Full Text Finder [Icon] => https://imageserver.ebscohost.com/branding/images/FTF.gif [MouseOverText] => Full Text Finder ) ) |
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => Clinical trial: the microbiological and immunological effects of synbiotic consumption – a randomized double-blind placebo-controlled study in active Crohn’s disease.
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Steed%2C+H%2E%22">Steed, H.</searchLink><br /><searchLink fieldCode="AR" term="%22Macfarlane%2C+G%2E+T%2E%22">Macfarlane, G. T.</searchLink><br /><searchLink fieldCode="AR" term="%22Blackett%2C+K%2E+L%2E%22">Blackett, K. L.</searchLink><br /><searchLink fieldCode="AR" term="%22Bahrami%2C+B%2E%22">Bahrami, B.</searchLink><br /><searchLink fieldCode="AR" term="%22Reynolds%2C+N%2E%22">Reynolds, N.</searchLink><br /><searchLink fieldCode="AR" term="%22Walsh%2C+S%2E+V%2E%22">Walsh, S. V.</searchLink><br /><searchLink fieldCode="AR" term="%22Cummings%2C+J%2E+H%2E%22">Cummings, J. H.</searchLink><br /><searchLink fieldCode="AR" term="%22Macfarlane%2C+S%2E%22">Macfarlane, S.</searchLink> ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => Alimentary Pharmacology & Therapeutics; Oct2010, Vol. 32 Issue 7, p872-883, 12p, 1 Diagram, 1 Chart, 6 Graphs ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22CROHN'S+disease%22">CROHN'S disease</searchLink><br /><searchLink fieldCode="DE" term="%22IMMUNE+response%22">IMMUNE response</searchLink><br /><searchLink fieldCode="DE" term="%22MICROORGANISMS%22">MICROORGANISMS</searchLink><br /><searchLink fieldCode="DE" term="%22PLACEBOS%22">PLACEBOS</searchLink><br /><searchLink fieldCode="DE" term="%22BIFIDOBACTERIUM%22">BIFIDOBACTERIUM</searchLink> ) Array ( [Name] => Abstract [Label] => Abstract [Group] => Ab [Data] => Aliment Pharmacol Ther 2010; 32: 872–883 Background Crohn’s disease is an inflammatory illness in which the immune response against gut microorganisms is believed to drive an abnormal immune response. Consequently, modification of mucosal bacterial communities, and the immune effects they elicit, might be used to modify the disease state. Aim To investigate the effects of synbiotic consumption on disease processes in patients with Crohn's disease. Methods A randomized, double-blind placebo-controlled trial was conducted involving 35 patients with active Crohn's disease, using a synbiotic comprising Bifidobacterium longum and Synergy 1. Clinical status was scored and rectal biopsies were collected at the start, and at 3- and 6-month intervals. Transcription levels of immune markers and mucosal bacterial 16S rRNA gene copy numbers were quantified using real-time PCR. Results Significant improvements in clinical outcomes occurred with synbiotic consumption, with reductions in both Crohn's disease activity indices ( P = 0.020) and histological scores ( P = 0.018). The synbiotic had little effect on mucosal IL-18, INF-γ and IL-1β; however, significant reductions occurred in TNF-α expression in synbiotic patients at 3 months ( P = 0.041), although not at 6 months. Mucosal bifidobacteria proliferated in synbiotic patients. Conclusion Synbiotic consumption was effective in improving clinical symptoms in patients with active Crohn's disease. [ABSTRACT FROM AUTHOR] ) Array ( [Name] => Abstract [Label] => [Group] => Ab [Data] => <i>Copyright of Alimentary Pharmacology & Therapeutics is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.) ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Identifiers] => Array
(
[0] => Array
(
[Type] => doi
[Value] => 10.1111/j.1365-2036.2010.04417.x
)
)
[Languages] => Array
(
[0] => Array
(
[Code] => eng
[Text] => English
)
)
[PhysicalDescription] => Array
(
[Pagination] => Array
(
[PageCount] => 12
[StartPage] => 872
)
)
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => CROHN'S disease
[Type] => general
)
[1] => Array
(
[SubjectFull] => IMMUNE response
[Type] => general
)
[2] => Array
(
[SubjectFull] => MICROORGANISMS
[Type] => general
)
[3] => Array
(
[SubjectFull] => PLACEBOS
[Type] => general
)
[4] => Array
(
[SubjectFull] => BIFIDOBACTERIUM
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Clinical trial: the microbiological and immunological effects of synbiotic consumption – a randomized double-blind placebo-controlled study in active Crohn’s disease.
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Steed, H.
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Macfarlane, G. T.
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Blackett, K. L.
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Bahrami, B.
)
)
)
[4] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Reynolds, N.
)
)
)
[5] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Walsh, S. V.
)
)
)
[6] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Cummings, J. H.
)
)
)
[7] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Macfarlane, S.
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 01
[M] => 10
[Text] => Oct2010
[Type] => published
[Y] => 2010
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-print
[Value] => 02692813
)
)
[Numbering] => Array
(
[0] => Array
(
[Type] => volume
[Value] => 32
)
[1] => Array
(
[Type] => issue
[Value] => 7
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Alimentary Pharmacology & Therapeutics
[Type] => main
)
)
)
)
)
)
)
|
| IllustrationInfo |